Imaging in oncology research

Small Animal Imaging: Basics and Practical Guide

Volumn , Issue , 2011, Pages 543-564

  Weber, Wolfgang A ^a   Kiessling, Fabian ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892285987     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-12945-2_35     Document Type: Chapter

References (100)

1. Andresen V, Alexander S, Heupel WM, Hirschberg M, Hoffman RM, Friedl P (2009) Infrared multiphoton microscopy: subcellular-resolved deep tissue imaging. Curr Opin Biotechnol 20:54-62
2. Aoyama C, Liao H, Ishidate K (2004) Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43:266-281
3. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q et al (2003) 3;-deoxy-3;-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791-3798
4. Bentolila LA, Ebenstein Y, Weiss S (2009) Quantum dots for in vivo small-animal imaging. J Nucl Med 50:493-496
5. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD (1996) Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 56:4630-4635
6. Bremer C, Tung CH, Weissleder R (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743-748
7. Brix G, Bahner ML, Hoffmann U, Horvath A, Schreiber W (1999) Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT-initial experience. Radiology 210:269-276
8. Cai W, Chen K, Li ZB, Gambhir SS, Chen X (2007) Dualfunction probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 48:1862-1870
9. Chen X (2006) Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 6:227-234
10. Chen X, Conti PS, Moats RA (2004) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 64:8009-8014
11. Cui K, Xu X, Zhao H, Wong ST (2008) A quantitative study of factors affecting in vivo bioluminescence imaging. Luminescence 23:292-295
12. Dandekar M, Tseng JR, Gambhir SS (2007) Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 48:602-607
13. de la Zerda A, Bodapati S, Teed R, Schipper ML, Keren S, Smith BR et al (2009) A comparison between time domain and spectral imaging systems for imaging quantum dots in small living animals. Mol Imaging Biol 11:127-133
14. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN et al (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61:110-117
15. Denk W, Strickler JH, Webb WW (1990) Two-photon laser scanning fluorescence microscopy. Science 248:73-76
16. Diagaradjane P, Orenstein-Cardona JM, Colon-Casasnovas NE, Deorukhkar A, Shentu S, Kuno N et al (2008) Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 14: 731-741
17. Dinkel J, Bartling SH, Kuntz J, Grasruck M, Kopp-Schneider A, Iwasaki M et al (2008) Intrinsic gating for small-animal computed tomography: a robust ECG-less paradigm for deriving cardiac phase information and functional imaging. Circ Cardiovasc Imaging 1:235-243
18. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R et al (2001) Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 98:9300-9305
19. Dunn KW, Sutton TA (2008) Functional studies in living animals using multiphoton microscopy. ILAR J 49:66-77
20. Flores JE, McFarland LM, Vanderbilt A, Ogasawara AK, Williams SP (2008) The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imaging Biol 10:192-200
21. Foley LM, Towner RA, Painter DM (2001) In vivo image-guided (1)H-magnetic resonance spectroscopy of the serial development of hepatocarcinogenesis in an experimental animal model. Biochim Biophys Acta 1526:230-236
22. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D et al (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47:999-1006
23. Gao X, Cui Y, Levenson RM, Chung LW, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969-976
24. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899
25. Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8:56-61
26. Gilad AA, McMahon MT, Walczak P, Winnard PT Jr., Raman V, van Laarhoven HW et al (2007) Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 25:217-219
27. Gilead A, Meir G, Neeman M (2004) The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. Int J Cancer 108:524-531
28. Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H et al (2008) New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 14: 2019-2027
29. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995
30. Hara T, Kosaka N, Kishi H (2002) Development of (18) F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187-199
31. Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4:182-193
32. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al (2001) Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785
33. Hnatowich DJ (1999) Antisense and nuclear medicine. J Nucl Med 40:693-703
34. Hoffman RM (2005) The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5:796-806
35. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S et al (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34:1936-1943
36. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS (2001) Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A 98:14595-14600
37. Johnson M, Karanikolas BD, Priceman SJ, Powell R, Black ME, Wu HM et al (2009) Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. J Nucl Med 50:757-764
38. Kang JH, Chung JK (2008) Molecular-genetic imaging based on reporter gene expression. J Nucl Med 49(suppl 2): 164S-179S
39. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K et al (2008) Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 35:999-1007
40. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16:116-122
41. Kiessling F, Farhan N, Lichy M, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MA, Semmler W, Fusenig NE, Delorme S (2004) Dynamic contrast enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF-receptor 2 blockade with DC101. Neoplasia 6:213-223
42. Kiessling F, Jugold M, Woenne EC, Brix G (2007) Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur Radiol 17:2136-2148
43. Kiessling F, Huppert J, Palmowski M (2009) Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 16:627-642
44. Kim KI, Chung JK, Kang JH, Lee YJ, Shin JH, Oh HJ et al (2005) Visualization of endogenous p53-mediated transcription in vivo using sodium iodide symporter. Clin Cancer Res 11:123-128
45. Kimura RH, Cheng Z, Gambhir SS, Cochran JR (2009) Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 69:2435-2442
46. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH et al (2003) In vivo high resolution threedimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 63: 6838-6846
47. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP et al (2007) A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13:992-997
48. Kovar JL, Simpson MA, Schutz-Geschwender A, Olive DM (2007) A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. Anal Biochem 367:1-12
49. Kovar JL, Volcheck W, Sevick-Muraca E, Simpson MA, Olive DM (2009) Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem 384:254-262
50. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-482
51. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM (2005) True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32:663-671
52. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287-294
53. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA et al (2004) Tumor localization of 16beta-18F-fluoro- 5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45: 366-373
54. Lederle W, Linde N, Heusel J, Bzyl J, Woenne EC, Zwick S et al (2010) Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am J Pathol 176:981-994
55. Lendvai G, Estrada S, Bergstrom M (2009) Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem 16:4445-4461
56. Li XF, Zanzonico P, Ling CC, O'Donoghue J (2006) Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat 5:147-155
57. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE et al (2000) In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18:321-325
58. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662
59. Mahmood U, Weissleder R (2003) Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2:489-496
60. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B et al (2009) Evaluation of a 1, 4, 7, 10-tetraazacyclododecane- 1, 4, 7, 10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240-5249
61. McGivan JD, Pastor-Anglada M (1994) Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 299(pt 2):321-334
62. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ et al (2005) Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307:538-544
63. Miles KA (2002) Functional computed tomography in oncology. Eur J Cancer 38:2079-2084
64. Modo M, Bulte J (2007) Cellular and molecular MR imaging. CRC, Boca Raton, pp 209-210
65. Montet X, Ntziachristos V, Grimm J, Weissleder R (2005) Tomographic fluorescence mapping of tumor targets. Cancer Res 65:6330-6336
66. Montet X, Figueiredo JL, Alencar H, Ntziachristos V, Mahmood U, Weissleder R (2007) Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 242:751-758
67. Moroz E, Carlin S, Dyomina K, Burke S, Thaler H, Blasberg R et al (2009) Real-time imaging of HIF-1a stabilization and degradation. Plos One 4:e5077
68. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G et al (2007) Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 21:378-383
69. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO (2009) Positron emission tomography imaging of druginduced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 106:16375-16380
70. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S et al (2005) Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61:1493-1502
71. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ et al (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907-5916
72. Ou G, Itasaka S, Zeng L, Shibuya K, Yi J, Harada H et al (2009) Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 75:463-467
73. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA et al (2008a) Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 68:7042-7049
74. Palmowski M, Huppert J, Ladewig G, Hauff P, Reinhardt M, Mueller MM et al (2008b) Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther 7:101-109
75. Palmowski M, Peschke P, Huppert J, Hauff P, Reinhardt M, Maurer M et al (2009) Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia 11:856-863
76. Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H et al (2007) Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 244:449-456
77. Plathow C, Weber WA (2008) Tumor cell metabolism imaging. J Nucl Med 49(suppl 2):43S-63S
78. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW et al (2008) Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105: 14342-14346
79. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D et al (2004) Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 64:6732-6739
80. Ray P, Tsien R, Gambhir SS (2007) Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res 67:3085-3093
81. Reinhardt M, Hauff P, Briel A, Uhlendorf V, Linker RA, Maurer M et al (2005) Sensitive particle acoustic quantification (SPAQ): a new ultrasound-based approach for the quantification of ultrasound contrast media in high concentrations. Invest Radiol 40:2-7
82. Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738
83. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW et al (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103:105-110
84. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T et al (2004) Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64:6101-6108
85. Serganova I, Humm J, Ling C, Blasberg R (2006) Tumor hypoxia imaging. Clin Cancer Res 12:5260-5264
86. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
87. Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA (2007) 18F-Fluoroestradiol. Semin Nucl Med 37:470-476
88. Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J et al (1996) Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56:4087-4095
89. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF et al (2001) Vessel size imaging. Magn Reson Med 45: 397-408
90. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y et al (2008) Early detection of erlotinib treatment response in NSCLC by 3;-deoxy-3;-[F]-fluoro-Lthymidine ([F]FLT) positron emission tomography (PET). PLoS One 3:e3908
91. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3;-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642-646
92. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033
93. Verrey F (2003) System L: Heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Archiv 445:529-533
94. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S (1998) Quantification of myocardial blood flow with ultrasound- induced destruction of microbubbles administered as a constant venous infusion. Circulation 97:473-483
95. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA (2008) Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14:3416-3426
96. Woo SK, Lee TS, Kim KM, Kim JY, Jung JH, Kang JH et al (2008) Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET. Nucl Med Biol 35:143-150
97. Wu AM (2009) Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50:2-5
98. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
99. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L et al (2009) Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5). Clin Cancer Res 15:5224-5233
100. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M et al (2009) Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 29:1125-1133